Neutrophil CD64 as a marker of infection in patients treated  with tocilizumab.
Matsui
Toshihiro
T
Department of Rheumatology, Sagamihara National Hospital, National Hospital Organization, 18-1 Sakuradai, Sagamihara, Kanagawa 228-8522, Japan. t-matsui@sagamihara-hosp.gr.jp
Komiya
Akiko
A
Shimada
Kota
K
Nakayama
Hisanori
H
Tohma
Shigeto
S
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000628:therapy; D015415:Biomarkers; D005260:Female; D006801:Humans; D007239:Infections / Q000276:immunology*; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology*; D017452:Receptors, IgG / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D017452:Receptors, IgG; C502936:tocilizumab